Ocumetics Reports Positive Three-Month First-in-Human Results for Accommodating Intraocular Lens

Ocumetics Technology Corp. announced positive three-month postoperative results from Group 1 patients in its first-in-human clinical study of the Ocumetics Accommodating Intraocular Lens. The results validate the company's core technology and represent a key clinical de-risking milestone as Ocumetics advances toward subsequent study phases. The Group 1 data met or exceeded all predefined internal benchmarks for safety, lens delivery, and foundational distance visual performance, successfully achieving the primary objectives required to progress the clinical program.

These first-in-human results demonstrate safe implantation, reliable delivery, and strong visual outcomes at this stage. Following a detailed review of the data with Dr. Raphael Vasquez, the primary surgeon, management remains fully confident in the accommodating intraocular lens technology. Based on this success, planning for Group 2 surgeries has been initiated. The study successfully validated the core technology and cleared the path to the next clinical phase, with patients experiencing meaningful improvements in everyday vision.

Group 1 patients entered the study with severe visual impairment, with some presenting uncorrected preoperative acuities as poor as 20/250, levels consistent with legal blindness. Post-implantation outcomes underscore both the clinical effectiveness and real-world impact of the Ocumetics Lens. All patient outcomes have met safety expectations. The profile of the patients selected had poor vision, and as a result of the implantations, they have experienced truly a life-changing event. From being classified legally blind, patients can now read, enjoy everyday life activities, and drive. The impact on their independence and sense of freedom has been remarkable.

The results from Group 1 can be best summarized as meeting expectations for safety profile, meeting and exceeding expectations for visual acuity outcomes, and meeting expectations for lens delivery system. Ocumetics continues to apply its rapid win-learn R&D approach, incorporating surgeon feedback in real time to further optimize performance. Based on insights from Group 1, the company has already implemented refinements to the lens delivery mechanism and initiated multiple lens optimization initiatives aimed at enhancing outcomes in Group 2.

Manufacturing and testing of optimized lens designs are currently underway. Group 2 surgeries are expected to be scheduled following completion of final lens testing and validation. The Group 1 results clearly demonstrated and confirmed the viability of the accommodating intraocular lens technology. This milestone materially strengthens the clinical foundation and positions Ocumetics to build momentum as it advances into Group 2. The company is excited to continue executing on its clinical and development roadmap. For more information about the study, visit https://www.ocumetics.com/webinar.